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Background: Alcoholic liver disease (ALD) is a significant cause of death and morbidity. Detection of liver fibrosis at
an early stage could provide opportunities for more optimal management. Serum markers of liver fibrosis offer an
alternative to biopsy. Evidence of the performance of biomarkers in ALD is needed and a systematic review to
evaluate available studies was conducted.
Methods: Electronic databases were searched. Studies were included if they evaluated paired samples of biopsy
and serum, and presented data as sensitivity, specificity, or ROC curves.
Results: 15 studies were included- median participant number = 146 (range 44–1034). Studies differed with respect
to patient populations. 6 single markers were evaluated (mostly Hyaluronic Acid), and ten combined panels.
Biomarkers could discriminate between people with severe fibrosis/cirrhosis with high diagnostic accuracy- HA
(median AUROC 0.79 range 0.69-0.93), panels (median AUROC 0.83 range 0.38-0.95). Significant heterogeneity
precluded pooling. Performance was poorer for detecting less severe fibrosis.
Conclusions: There are limited numbers of small studies evaluating the accuracy of biomarkers in identifying
fibrosis on biopsy in ALD. Some showed promise (both HA alone and some panels) in the identification of cirrhosis/
severe fibrosis and could be used to rule it out in heavy drinkers. Biomarkers less accurate with less severe fibrosis.
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Alcohol related deaths are an important health concern
worldwide. In the UK 85% of such deaths are due to
cirrhosis and recent epidemiological studies have shown
that although mortality rates from cirrhosis are falling in
most countries absolute rates remain high, and in the UK
and Eastern Europe the trend is upwards with 18% rise in
deaths from alcohol related causes between 2000 and
2004 [1-5]. In these countries alcohol consumption is high
and increasing and patterns of drinking have changed over
the past three decades –binge drinking and a rise in
hazardous drinking in younger women. Alcoholic Liver
Disease (ALD) therefore represents a serious public health* Correspondence: jules@soton.ac.uk
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reproduction in any medium, provided the orproblem and is likely to get worse in the UK in the coming
decades.
Clinicians and patients require accurate information
about the degree of liver fibrosis in ALD to assess disease
severity in order to predict outcome, guide management
decisions and monitor disease. Detection of fibrosis in
people drinking hazardously at an early stage or before
clinical symptoms of hepatic decompensation could pro-
vide opportunities for more optimal management. This is
a challenge in a disease process with few characteristic
symptoms or signs. The current reference standard to
ascertain the stage of fibrosis is histology obtained through
liver biopsy. This is an invasive test and subject to limita-
tions both in its acquisition (sampling error, length of
biopsy, morbidity and mortality), subsequent analysis
(intra and inter observer variability) and inherent draw-
backs as a reference standard (ordinal categorical variable
representing continuous biological process) [6-8]. In theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to accurately evaluate fibrosis. Serum markers of liver
fibrosis offer an attractive alternative to liver biopsy, as
they are less invasive, may allow dynamic calibration of
fibrosis, and are potentially more cost effective. Evi-
dence of the diagnostic performance of such serum
markers of liver fibrosis in Chronic Liver Disease are
needed to assess the clinical utility and effectiveness of
such tests in the diagnosis, prognosis and management
of liver disease. Systematic reviews of the diagnostic
performance of serum markers in chronic hepatitis C
(CHC) and non alcoholic fatty liver disease (NAFLD)
have been published but none so far on the evaluation
of markers in ALD [9-13].
In order to provide such evidence, a systematic review
was conducted to locate, collate, appraise and analyse
studies that evaluated the performance of serum markers
in the diagnosis of liver fibrosis in ALD.
Methods
A systematic literature review was conducted following
accepted published principles to ascertain the diagnostic
performance of serum markers of liver fibrosis [14].
Sources searched included:
 Electronic databases 1980 – April 2009
 Cochrane Library 2009
 Reference lists from relevant articles
MEDLINE, EMBASE were searched using a search stra-
tegy derived from the literature (search strategy available
from authors). Search terms were added following initial
searches as appropriate.
No authors were contacted for further information.
Inclusion/exclusion criteria
A serum marker was defined as any measure that could
be derived from a blood sample
Studies were included if they;
 were systematic reviews, meta-analyses or primary
studies of diagnostic tests
 were written in English
 used liver biopsy as a reference standard
 presented data as sensitivity or specificity or
diagnostic accuracy or receiver operator
characteristic curve (ROC) analyses
 included >30 participants (as smaller studies will be
underpowered to produce precise estimates of test
performance and would be more likely to produce
zero denominator effects in a 2 × 2 table.
Confidence intervals would be very wide and
inclusion in SROC where studies are unweighted
may result in skewed unreliable results). data were extractable by cause of liver disease and
by fibrosis stage.
Studies were excluded if data were presented only in
abstract form.
Studies identified by the search strategy were assessed
for inclusion by two reviewers (JP and ING).
Data extraction strategy
Data extraction was undertaken by one reviewer (JP) and
checked by a second reviewer (ING) with any disagree-
ments being resolved through discussion. A third reviewer
(PR) was consulted to resolve persisting issues. Information
collected included patient demographics, test assay details;
background prevalence of fibrosis severity, risk factors,
histological parameters, statistical methods used, and test
performance characteristics consistent with columns in
Tables 1 and 2.
Data analysis/synthesis
Data are presented with full tabulation of results of
included studies.
Where data were available, 2 × 2 tables were constructed
to derive sensitivity, specificity, predictive values, likelihood
ratios (LR) and diagnostic odds ratios (DOR) at each
threshold value. (Accepted levels for robust tests are - LR =
<0.1, and + LR = >10, >5 and <0.2 give strong diagnostic
evidence. For DOR reasonable test performances would be
>30). Severity of fibrosis was defined by authors (for locally
derived classifications) and as mild = stages 0,1, moderate/
severe stages 2–4, severe fibrosis stages 3,4 and cirrhosis
stage 4 for those using METAVIR/Scheuer classifications.
Results
The electronic search yielded 463 abstracts which were
read in full. 41 full papers were retrieved of which 26 were
excluded leaving 15 studies in separate populations to be
included in the review (see Table 2). Reasons for exclusion
were (may be >1 /study);
 Not primary study (editorial/non systematic review)
n = 3
 Outcome was not fibrosis (usually alcoholic hepatitis)
n = 6
 Participants <30 n = 1
 No results separable for ALD alone n = 6
 No results reported as sensitivity, specificity, ROC
curves, diagnostic accuracy n = 11 (Most of these
studies reported correlation coefficients/differences
in means of serum markers between group with
fibrosis and those with less fibrosis).
 No results for fibrosis alone separable from data that
combined steatosis with fibrosis or fibrosis/cirrhosis
with acute alcoholic hepatitis (AH) n = 4
Table 1 Characteristics of studies evaluating serum markers in alcoholic liver disease
Study Author:
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221 Patients with active history of
excess alcohol consumption
admitted to hospital (24%
decompensated cirrhosis)
and with available histology
>50 g alcohol daily
for 1 year
31(64) 47 77 METAVIR Fibrotest (α2M, apoA1,
bilirubin, GGT, haptogloblin,
corrected for age + sex)
Stage 0 7% Mean length 15 mm
± 05
Stage 1 329%
Stage 2 22% Frags = 2.2 ± 0.1
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Table 1 Characteristics of studies evaluating serum markers in alcoholic liver disease (Continued)
Study Author: Yr
























Nguyen –Khac 2008 [28] 103 Patients with attending hepato-GI,
alcoholism & Int Med depts. who
were HBV- and HCV- without
decompensated cirrhosis who
agreed to have liver biopsy
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mean 19 yrs)
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Stage 0 7% iopsy/ serum
1 month apart
Fibrometer (HA PT α2M)
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Table 2 Diagnostic performance of single markers
Degree of fibrosis tested Study No. AUC Cut off used Sens Spec PPV NPV LR + (95% CI) LR – (95% CI)
HA
Cirrhosis Oberti [18] (1997) 109* n/r 60mcg/l 100 60 78 97 2.5 (1.7,3.6) 0.02(0.004,0.18)
Tran [19] (2000) 146 n/r 60mcg/l 100 86 83 99 6.8 (4.1,11.4) 0.02 (0.004,0.1)
Plevris [21] (2000) 70 n/r 100mcg/l 87 89 n/a n/a 8.0 0.15
Stickel [23] (2003) 87 0.78 250mcg/l 100 69 35 98 3 (2.0, 4.28) 0.10 (0.02,0.69)
Naveau [25] (2005) 221 0.93 (0.91,0.95) n/r n/r n/r n/r n/r n/r n/r
Nguyen-Khac [28] (2008) 103 0.80 (0.68,0.92_ n/r n/r n/r n/r n/r n/r n/r
Stage 012 vs34 Stickel [23] (2003) 87 0.76 55.5 mcg/l 83 69 67 83 3(1.7, 4.2) 0.26 (0.13,0.53)
Nguyen-Khac [28] (2008) 103 - 0.83 (0.74-0.92)
Lieber [29] (2008) 247 0.69
F01vs 234 Naveau [25] (2005) 221 0.79 (0.76-0.82) n/r n/r n/r n/r n/r n/r
Nguyen-Khac [28] (2008) 103 0.80 (0.70-0.92) n/r n/r n/r n/r n/r n/r n/r
Degree of Fibrosis tested Study No. AUC (95%CI) Cut off used Sens Spec PPV NPV LR + (95% CI) LR-(95% CI)
F0 vs 1-4 Nguyen-Khac [28] (2008) 103 0.76 (0.58-0.94) n/r n/r n/r n/r n/r n/r n/r
P3NP
F012 vs34 Gabrielli [15] (1989) 44 n/r 16 ng/ml 71 50 n/r n/r 1.4 0.6
Lieber [29] (2008) 247 0.67
F0 vs F1-6 Gabriella [15] (1989) 44 n/r 16 ng/ml 90 59 n/r n/r 2 0.2
Li [17] (1994) 44 0.80 ±0.07 1.1 U/ml 45 100 94 44 6.8 (0.99, 47) 0.6 (0.42, 0.82)
Prothrombin Index**
Cirrhosis Oberti [18] (1997) 109 n/r 85% n/r n/r n/r n/r n/r n/r
Croquet [22] (2002) 240 n/r 80% 81 99 99 85 101(14.3,713.5 0.2 (0.13,0.28)
Tran [19] (2000) 146 n/r 85% 83 93 89 89 12.1(5.56,26.5) 0.2 (0.1,0.33)
TIMP1
F012 vs 34(advanced fibrosis) Lieber [29] (2008) 247 0.68 n/r n/r n/r n/r n/r n/r
Any fibrosis (1994) Li [17] 44 0.96 ±0.03 313 ng/ml n/r n/r n/r n/r n/r n/r
YKL
Cirrhosis Tran [19] (2000) 146 n/r 330mcg/l 51 89 75 74 5 (2.4,8.6) 0.5 (0.4,0.7)
ApoA1
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Studies were conducted between 1989 and 2009. Study
characteristics are shown in Table 2. The median age of
participants in included studies was 50 years (range 44–
65 years), 77% were male (range 63-100%) and the median
number of study participants was 146 (range 44–1034).
The median background prevalence of serious fibrosis/cir-
rhosis was 41% (14-59%). All of the studies were conducted
in secondary/tertiary settings.
There was marked differences between the studies. Dif-
ferent scoring systems were used: METAVIR (or modified
METAVIR) n = 6; Scheuer n = 1; Ishak n = 2; Knodell n = 1;
Worner /Lieber n = 1, and locally generated n = 5 (mostly
dividing fibrosis into mild, moderate or severe). 13/15 stu-
dies presented data that showed the performance of the
markers in identifying cirrhosis/severe fibrosis (METAVIR
stages 4 /3,4), 5/15 reported significant fibrosis (METAVIR
stages 2–4), and 3/15 studies reported information identi-
fying any fibrosis). All of the studies evaluated performance
of markers using cross sectional data for paired samples of
histology and serum. 14/15 studies recruited prospectively,
and half recruited consecutive patients. There was het-
erogeneity of patient selection. Although all partici-
pants were recruited in a hospital setting, some were
hospitalized and some were out- patients. There were
also differences in both in the inclusion criteria and
daily alcohol consumption. Inclusion criteria reported
were patients with previously diagnosed ALD, and or
“alcoholism” or heavy alcohol consumption, or patients
admitted for rehabilitation/detoxification/alcohol with-
drawal symptoms. The daily consumption of alcohol
(where reported) varied with 1 study recruiting patients
drinking >100 g of alcohol/day, 4 studies >80 g, and 6
studies >50 g, Inclusion criteria used a varied number
of years drinking at these levels (range 5–10 years)
reported, with one study having a mean alcohol con-
sumption of 225 g/day for a mean of 19 years [29] (See
Table 2). Some studies used the same population of
patients with ALD to report the performance of different
serum markers- single and panel tests- in two publications
[25,30]. Another research group reported two studies
which also used the same patient population, with the
earlier study reporting results from 109 patients with
compensated ALD recruited in 1994–95 and the later
study adding further patients from 1997–98 and reporting
from the whole cohort (n = 240) [2,18]. Both studies were
included as data reported were different, with the earlier
study reporting the performance of two serum markers
and the later study having more participating patients but
reporting results for one marker. This may reflect the dif-
ficulty in recruiting and retaining patients with this liver
disease
The significant heterogeneity precluded pooling of
results. Results are presented separately for single markers(Table 2) and for marker panels (Table 3) in the identifica-
tion of cirrhosis (F4 METAVIR) cirrhosis, /severe fibrosis
(F3/F4 METAVIR) and ‘significant’ fibrosis (F2-4-Meta-
vir). There were 13 separate markers evaluated- 6 as sin-
gle markers, and the remaining as components of 10
panels. 5/6 of those reported as single markers were also
used in the panels. Three studies reported sensitivity and
specificity at more than one threshold [25-27].
Single markers
All single markers studies were heterogeneous with respect
to the grade of fibrosis identified by the test, and the thres-
holds reported (Table 2).
i) Hyaluronic Acid (HA)
The most commonly measured single marker was HA
(7 studies, total n = 1360), The studies were all small
(n = ~200) and where reported different thresholds of HA
concentration for positive test results were used (range 55
mcg/l - 250 mcg/l). Not all studies gave sufficient detail of
analytical methods used to determine HA, but there were
differences in methods used in those that did report the
assay-a radiometric binding protein assay (used by three
included studies); an enzyme linked binding protein assay,
and immunoassay using a magnetic particle separation
technique (2 studies). The inclusion criteria with respect
to alcohol consumption were different for each study
(>100 g alcohol daily; >80 g for >5 years, , >50 g daily alco-
hol for >5 yrs, >50 g alcohol daily for 1 year) as was the
size of the studies (range n = 70-247). The severity of ser-
ious fibrosis varied between studies, with prevalence of
cirrhosis in one study [22] being less than half that in the
other studies
Seven studies evaluated its performance in the identifi-
cation of cirrhosis or cirrhosis /severe fibrosis although
only 4 of these reported AUROC values. One study
reported results for the identification of patients with no
or mild fibrosis. The AUROCs for the 3 studies identifying
cirrhosis were discrepant −0.78, 0.80 and 0.93. The me-
dian AUC for predicting severe fibrosis/cirrhosis =0.79
(range 0.69-0.93). Overall the LRs and predictive values
showed that HA was better at excluding cirrhosis/ severe
fibrosis than detecting it, with NPVs consistently high
~90% for cirrhosis.
There are two direct comparisons of a panel and HA.
These showed differing results. In the larger study [25]
there was no significant difference between panel (Fibrot-
est) and HA at both identifying cirrhosis and moderate
/severe fibrosis. In the other study [28] most of the panel
tests had greater AUC values in predicting cirrhosis than
HA alone (but 95% CI were overlapping) but at lower
levels of fibrosis the performance of HA and panels are
more similar. Overall HA was better at identifying
Table 3 Panel marker tests measuring fibrosis in ALD
Fibrosis grade Study No. Test AUROCS Cut
off
Sens Spec PPV NPV LR+ -LR
(95% CI) (95% CI)
Cirrhosis Poynard [16] 1991 624 PGA n/r 6 85 85 70 93 5.6 (4.5 7.01) 0.18 (0.12,0.25)
Cirrhosis Tran [19] 2000 146 Tran n/r 76 99 98 86 66.8 (9.5,471.2) 0.24 (0.15,0.37)
Cirrhosis Naveau [25] 2005 221 Fibrotest 0.95 (0.94, 0.96) 0.3 84 41 39 85 1.4 (1.2,1.7) 0.39 (0.2,0.70)
0.7 60 72 49 80 2.1 (1.6,2.9) 0.55 (0.40,0.75)
Cirrhosis Lieber [27] 2006 1034 APRI 0.79 >2.0 17 86 56 50 1.2 (0.9,1.6) 1.0 (0.92,1.02)
Cirrhosis Nguyen –Khac [28] 2008 103 Fibrotest 0.84 (0.72,0.97) n/r n/r n/r n/r n/r n/r n/r
Fibrometer 0.85 (0.74,0.96) n/r n/r n/r n/r n/r n/r n/r
Hepascore 0.76 (0.63,0.90) n/r n/r n/r n/r n/r n/r n/r
APRI 0.56 (0.38,0.73) n/r n/r n/r n/r n/r n/r n/r
PGA 0.89 (0.82 0.97) n/r n/r n/r n/r n/r n/r n/r
PGAA 0.83 (0.73-0.93) n/r n/r n/r n/r n/r n/r n/r
Cirrhosis Naveau [30] 2009 218 Fibrotest 0.94 (0.90,0.96) 0.56 90 n/r n/r n/r n/r n/r
0.78 n/r 90 n/r n/r n/r n/r
>0.30 100 50 47 100 2.0 0.50
>0.70 87 86 73 94 6.2 0.16
Fibrometer 0.94 (0.90,0.97) 0.92 90 n/r n/r n/r n/r n/r
0.997 n/r 90 n/r n/r n/r n/r
>0.50 99 62 54 99 2.6 0.38
>1.0 88 88 76 94 7.3 0.14
Hepascore 0.92 (0.87,0.97) 0.97 90 n/r n/r n/r n/r n/r
0.99 n/r 90 n/r n/r n/r n/r
Forns 0.38 (0.27,0.47) n/r n/r n/r n/r n/r n/r n/r
APRI 0.67 (0.59,0.75) n/r n/r n/r n/r n/r n/r n/r
FIB4 0.80 (0.72,0.86) n/r n/r n/r n/r n/r n/r n/r
F012vs 34 Severe Rosenberg [24] 2004 64 ELF 0.94 (0.84, 1.00) 0.087 100 17 75 100 1.2 (1.1, 1.4) 0.06 (0.01, 0.3)
0.431 93 100 100 86 68 (37,124) 0.08 (0.05,0.1)
F012vs 34 Severe Nguyen –Khac [28] 2008 103 FT 0.80 (0.7,0.9) n/r n/r n/r n/r n/r n/r n/r
Fibrometer 0.88 (0.8,0.95) n/r n/r n/r n/r n/r n/r n/r
Hepascore 0.83 (0.74,0.93) n/r n/r n/r n/r n/r n/r n/r
APRI 0.43 (0.30,0.56) n/r n/r n/r n/r n/r n/r n/r


















Table 3 Panel marker tests measuring fibrosis in ALD (Continued)





F01 vs 2-4 Mod/severe Cales [26] 2005 95 Fibrometer 0.96 (0.94, 0.98) n/r 92 93 99 76 18 (2.7,125) 0.08 (0.2)
F01vs 2-4 Mod-severe Naveau [22] 2005 221 Fibrotest 0.84 (0.81 0.87) 0.3 84 66 81 70 2.5 (1.8,3.4) 0.25 (0.16,0.40)
0.7 55 93 93 54 7.4 (3.3,16.1) 0.5 (0.4,0.6)
F01vs2-4 Mod severe Lieber [27] 2006 507 APRI 0.70 0.2 94 26 71 68 1.3 (1.2,1.4) 0.24 (0.17,0.33)
0.6 47 82 84 44 2.6 (2.0,3.3) 0.65 (0.6,0.71)
1.0 21 90 80 37 2.1 (1.5, 3.0) 0.88 (0.83,0.92)
1.6 13 95 83 36 2.5 (1.5,4.1) 0.92 (0.88,0.95)
2.0 9 97 86 35 3.1 (1.6,6.1) 0.94 (0.91,0.96)
F01vs2-4 Mod severe Nguyen –Khac [28] 2008 103 Fibrotest 0.79 (0.69,0.90) n/r n/r n/r n/r n/r n/r
Fibrometer 0.82 (0.72,0.93) n/r n/r n/r n/r n/r n/r
Hepascore 0.76 (0.64,0.88) n/r n/r n/r n/r n/r n/r
APRI 0.54 (0.4-0.68) n/r n/r n/r n/r n/r n/r
PGA 0.78 (0.68,0.89) n/r n/r n/r n/r n/r n/r
PGAA 0.81 (0.71,0.91) n/r n/r n/r n/r n/r n/r
F01vs2-4 Mod severe Naveau [30] 2009 218 Fibrotest 0.83 (0.77,0.88) 0.23 90 n/r n/r n/r n/r n/r
0.64 n/r 90 n/r n/r n/r n/r
>0.30 88 52 76 72 1.8 0.55
>0.70 43 97 96 50 14.3 0.07
Fibrometer 0.83 (0.77,0.87) 0.11 90 n/r n/r n/r n/r n/r
0.95 n/r 90 n/r n/r n/r n/r
>0.50 74 74 83 62 2.85 0.35
1.0 55 95 95 55 11.0 0.09
Hepascore 0.83 (0.77,0.88) 0.25 90 n/r n/r n/r n/r n/r
0.94 n/r 90 n/r n/r n/r n/r
Forns 0.38 (0.30,0.46) n/r n/r n/r n/r n/r n/r n/r
APRI 0.59 (0.51,0.67) n/r n/r n/r n/r n/r n/r n/r
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0.80) or milder fibrosis.
ii) Other single markers
There were more limited data on five other single mar-
kers, with only three studies presenting AUROC analyses.
Prothrombin index had high LR + and predictive values in
the identification of cirrhosis in two studies. One study
reported performance of TIMP1 and PIIINP in the same
population of patients as single markers and as part of a
panel. The study found that the AUROC values were lower
than in other studies of the same markers [29]. However
this study population differed from the other studies in
having a very high alcohol consumption over a long period
of time
Marker panels
Cirrhosis/severe fibrosis (Figure 1, Table 3). Eight studies
assessed the performance in detecting cirrhosis/severe
fibrosis, five of which reported AUROCs. Four studies were
external validations of previously derived panels [25,27-30].
Several panels (Fibrotest, Fibrometer, Hepascore, ELF)
showed promise in detection of cirrhosis with AUROCs
>0.9, although one was small (ELF n = 64), and one showed
no statistically significant difference to HA in direct com-
parison (Fibrotest). Common components of these panels
are HA (in 3 panels), alpha macroglobulin (in 2 panels),
GGT (in 2 panels). One panel (Tran index) reported a very
high specificity and PPV compared to other panels. Sim-
pler panels with ≤3components (for example PGA- Pro-
thrombin Index, GGT and Apolipoprotein A1) performed
as well as more complex panels –in a direct comparison
AUROCs for cirrhosis PGA 0.89 Vs Fibrotest 0.84 Vs
Hepascore 0.76, and for severe fibrosis/cirrhosis AUROCs
PGA 0.84 Vs Fibrotest 0.80 Vs Hepascore 0.83 although
this was only in one small study [25].
(ii) Moderate /severe fibrosis (Biopsy stages 2–4) The
performance of eight panels were reported of which
three had AUROCs >0.8 in detection of moderate/severe
fibrosis, Three studies reported results for Fibrometer,
with a varying range of AUROCs (0.96, 0.83, 0.82, total
patients n = 416). Fibrotest AUROCs were 0.84,0.83,
0.79) (total n = 324); and it was not significantly more
accurate than HA alone in direct comparison). Two
studies reported results for Hepascore (AUCs 0.76, 0.83)
total n = 321. Other panels had poorer performance in
detecting moderately severe fibrosis.
Three studies reported results for APRI [24,25,27]
( AUCs 0.70, 0.54 0.59) total n = 828) and Forns index
(AUC 0.38 95% CI 0.30,0.46). Those panel test external
evaluations performed by groups other than the original
authors showed a lower diagnostic performance. In
general, panels of markers reported lower diagnosticperformance in the detection of lesser stages of fibrosis
than in cirrhosis [25,27-30].
Discussion
A systematic review of the diagnostic performance of
serum markers in identifying liver fibrosis on biopsy in
patients with ALD using standard methodology found 15
primary studies. The evaluations used 13 different markers,
for single markers most commonly HA (n = 7), and 10
marker panels. Serum markers were able to identify those
people with severe fibrosis/cirrhosis with reasonable
diagnostic accuracy (based on AUROCs). HA as a single
marker performed well in identifying cirrhosis, as do some
panels of markers. The performance of the serum markers
was poorer at identifying lower grades of fibrosis, although
few studies evaluated this. The paucity of the literature
precluded further conclusions and summative analysis was
not possible due to study heterogeneity.
The evidence base for serum markers in ALD lags behind
that of Hepatitis C and non alcoholic fatty liver disease.
The studies are fewer in number, have fewer participants,
vary considerably in inclusion criteria, and have a higher
prevalence of cirrhosis/severe fibrosis than in similar stu-
dies in Hepatitis C and NAFLD. They also tend to be older
studies than other liver disease aetiologies, being less
informed by recent advances in the rigour and standardisa-
tion required from design and reporting of diagnostic
studies [31]. More recent studies have evaluated panels
(two of which were external validation studies). Panels
varied in their individual constituents, and in the number
of components. Generally the values of AUROCs of panel
tests in patients with ALD in predicting cirrhosis /sever
fibrosis are comparable with those in NAFLD or Hepatitis
C. For example in a metaanalysis of Fibrotest in Hepatitis C
the mean AUROC for predicting significant fibrosis was
reported as 0.77 (95% CI 0.75, 0.79) and in NAFLD 0.81
(95% CI 0.74 0.86) [2], and a summary AUROC for cirrho-
sis 0.82 [32]. Certain panels such as APRI seem to perform
less well in ALD than in Hepatitis C. Summary AUROC for
significant fibrosis was reported as 0.76 (95% CI 0.74 0.79)
and for cirrhosis 0.82 (95% CI 0.79 0.86) [33,34].
There have been reports in the literature of the effect of
current heavy alcohol consumption on circulating serum
markers which may limit their performance in identifying
the chronic effect of alcohol on fibrosis in patients who
may be current drinkers. The mode of action of alcohol on
the markers is unclear. Animal models have shown that
alcohol may have an effect on serum markers such as HA
in several ways- by alteration of communication between
liver cells thereby affecting HA clearance and by direct
effect on induction of hepatic sinusoidal endothelial cell
dysfunction [35,36], Studies have shown that some markers
are more susceptible to influences of acute consumption
but results are not consistent. One study reported that
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Figure 1 Summary figure of the AUC results for serum markers in ALD in the identification of cirrhosis, significant fibrosis (2–4)
and any fibrosis. AUC values (where reported) for all serum markers studies in patients with ALD identifying cirrhosis, significant fibrosis or any
fibrosis with 95% CI (where reported). Most studies are small (wide confidence intervals), varying in threshold reported, and where >1 study,
per serum marker results are inconsistent.
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unaffected (PIIINP, TIMP1), and some very variable (HA)
[37]. One small study reported that mean levels of PIIINP
but not TIMP1 rise with abstinence [38]. This confirmed
the results from an earlier study which showed similar
effect of alcohol on PIIINP [38] Direct studies of effects of
alcohol on serum markers in clinical studies involve very
small numbers and few studies have reported in the last
5 years. Most alcohol status (were reported ) is self report
with some studies using collateral evidence when available.
The included studies in this review did not all report
current drinking status in detail. In 4 studies included
patients were in-patients for alcohol withdrawal /rehabilita-
tion, in 2 studies the patients were not abstinent. More data
from large robust studies are needed to properly evaluate
the influence of current alcohol intake (ideally quantified
with objective measures/triangulated evidence) on markers,
reporting results in terms of level of alcohol consumption
and time of abstinence.
A major concern in drawing overall conclusions from
this review is the considerable heterogeneity of the study
populations. Whilst all included studies recruited patients
from specialist clinics in secondary or tertiary settings
(there were no studies set in primary care), there was vari-
ation in the population characteristics, such as level of al-
cohol consumption, and differences in the prevalence of
severe fibrosis. This may lead to spectrum bias influencing
diagnostic performance and additionally, affect generalis-
ability. Design of the studies differed with variation in re-
cruitment methods and inclusion criteria. All patients had
to have had a biopsy (from inclusion criteria) which could
introduce verification bias compared to those patients
with excess alcohol consumption not selected for biopsy
having a different disease severity than those who were
selected. Only four studies reported any parameters by
which biopsy quality could be judged, and half of these
reported findings stratified by biopsy quality. Even when
the tests were similar between studies, the thresholds used
were different or not reported. Direct comparison between
studies was made more difficult by the use of a range of fi-
brosis staging systems, largely locally generated. There was
heterogeneity and lack of standardization of analytical
methods used for the markers measurements and as these
different assays may not be well correlated, external validity
may be reduced and the determination of a single generalis-
able threshold remains problematic for those markers
assayed locally. Access and availability of serum markers
using commercial automated platforms may address this
issue. There was incomplete reporting of co-morbidities
and diagnostic test results, making appraisal and summative
assessment difficult. The paucity of studies which looked at
direct comparisons between panels, and between single
marker and panels make it difficult to say one panel is more
accurate than another. It is clear from this systematicreview that the current serum markers are promising, im-
proving and may provide additional diagnostic information
in the identification and management of people with ALD.
The limitations of this review include lack of data to
perform summative analyses and a focus on the ability of
diagnostic tests to identify fibrosis alone. Detection of
inflammation has not been addressed. Issues of spectrum
bias which may have an impact on performance characte-
ristics of the tests making direct comparisons between stu-
dies problematic, and this has not been directly addressed
in this review. This is due to several main problems in
accounting for such as bias. The first is a lack of a univer-
sally accepted system of dealing with this issue, especially in
this group of patients with ALD. There have been some
methodological suggestions published by one group in
chronic Hepatitis C [39], who have used this method in a
study in ALD patients [30]. Authors used standard popula-
tion of same prevalence for all fibrosis stages and currently
it is unclear if this has external validity or international
acceptance by professionals working in this field. In
addition the studies included in this review are older, use
different classification systems for histology and have
inconsistent and incomplete reporting of the individual
stages of study participants. All of this makes accounting
for spectrum bias problematic, complex and of questio-
nable validity in this review. However it is an important
issue and should be borne in mind when looking at results
between studies.
Clinical implications
For preventing and managing ALD it is important to iden-
tify those patients who are drinking hazardously and have
clinically silent severe fibrosis/cirrhosis in order to focus
interventions, to begin to screen for varices and Hepato-
cellular carcinoma or to prepare for possible liver trans-
plant. Data presented in this review suggest that marker
panels could be used effectively in this situation. It would
be clinically useful to patients and clinicians to identify the
proportion of hazardous drinkers who have developed liver
disease to monitor disease progress more closely and to
offer an opportunity for strategies aimed at reduction/ab-
stention. Repeated serum marker measurement showing
rise or decline in results may have an impact on lifestyle
choices again allowing scope for reduction in alcohol con-
sumption. These are speculative ideas and require further
research. This group of patients often has erratic attend-
ance at outpatient and biopsy appointments and may
present in settings where invasive tests are inappropriate/
difficult (e g prison). Access to non-invasive tests of liver fi-
brosis would be useful in the management of such patients.
Future research
Large studies of patients with ALD need to be designed
which can directly compare and validate in external
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cation of new markers or enhancement of existing tests to
identify any, mild or moderate fibrosis. For example, meth-
ods such as proteomics and metabonomics may identify
markers that can be incorporated into existing or new
panels of markers, either in isolation or in combination
with quantitative imaging techniques (such as elastogra-
phy). This process might be facilitated by establishing
an international reference library and quality assurance
scheme. The evaluation of diagnostic performance should
be accompanied by parallel evaluation of test performance
for properties such as reproducibility, stability and linearity.
Further work is needed to ascertain the diagnostic perform-
ance of markers in primary care setting. The limitations of
liver biopsy may create a glass ceiling for potential non-
invasive tests, and future studies should consider use of
clinical outcomes as the reference standard. The few studies
that have been reported in the literature on performance of
serum markers in ALD predicting clinical outcomes rather
than fibrosis have shown good performance for some
panels of serum markers [27]. Fibrotest, Hepascore and
Fibrometer A has been shown to be able to predict liver
related mortality at 5 years and 10 years (AUC= 0.79 (95%
CI 0.68,0.86) 0.77(95% CI 0.69,0.85) 0.80(95% CI 0.71,0.87)
respectively, at least as well as biopsy (AUC 0.77 (95% CI
0.70,0.83). Forns index, APRI and FIB 4 had lower perform-
ance in predicting liver related mortality -AUCs 0.40 (95%
CI 0.30,0.49), 0.60 (95% CI 0.50,0.69), 0.65 (95% CI 0.54
0.74 respectively. In a smaller population of patients with
ALD the predictive performance of the ELF test has also
shown AUC 0.80 (95% CI 0.70, 0.89) for liver related mor-
bidity/mortality at 7 years (personal communication with
Authors). Additional larger studies that can evaluate and
compare performance of non invasive methods in predict-
ing clinical outcomes in patients with ALD are needed.
In summary, none of the serum markers reported so far
in the literature appear to have a very good performance
for fibrosis severity less than moderate/severe fibrosis/
cirrhosis. In general, performance decreases as severity of
fibrosis being identified/ruled out decreases. HA shows
some promise as a single marker in ruling out cirrhosis and
to an extent severe fibrosis, but it is hard to know what
threshold to use. Other single markers have less good
performance when used alone. Some Panels (Fibrometer,
Fibrotest Hepascore, and ELF) show promise in diagnosing
cirrhosis/severe fibrosis but studies in ALD have small
numbers.
Conclusion
A systematic evaluation of the evidence of the diagnostic
performance of serum markers of fibrosis in ALD has
shown that there are few small studies published which
show that serum markers are able to identify cirrhosis/
severe fibrosis with good diagnostic accuracy, althoughstudy heterogeneity in design and outcome precludes
pooling. In clinical practice, this may allow earlier exclu-
sion of liver damage in hazardous drinkers permitting
earlier and targeted interventions. The limitations of the
liver biopsy may create a glass ceiling for potential
non-invasive tests, and in this regard more studies using
clinical outcomes should be evaluated.
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